Nanobiotix (NASDAQ:NBTX) Upgraded at Wall Street Zen

Key Points

• Nanobiotix has been upgraded to a "hold" rating by Wall Street Zen, following multiple research reports that feature varied ratings from other analysts.
• The company's stock is currently noted at $19.20, with a one-year price range between a low of $2.76 and a high of $30.35, indicating significant volatility.
• Nanobiotix focuses on developing products for cancer treatment, with its lead candidate, NBTXR3, targeting various types of cancer, including soft tissue sarcoma and non-small cell lung cancer.

Nanobiotix (NASDAQ:NBTX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "hold" rating in a research report issued to clients and investors on Saturday.

NBTX has been the subject of several other research reports. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Leerink Partners set a $14.00 target price on shares of Nanobiotix in a research note on Thursday, September 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $11.00.

Nanobiotix Stock Performance

NASDAQ NBTX opened at $19.20 on Friday. Nanobiotix has a 1 year low of $2.76 and a 1 year high of $30.35. The company has a fifty day moving average of $15.54 and a two-hundred day moving average of $8.44.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.